Biosimilar versions of several blockbuster drugs, including AbbVie’s Humira (adalimumab), Roche’s Herceptin (trastuzumab) and Avastin (bevacizumab), and Amgen’s Neulasta (pegfilgrastim) are under review at the European Medicines Agency.
The EMA publishes a monthly table of products that are under evaluation by the agency’s scientific committee, the CHMP, although...





